Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 16/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 16/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223975 | 0.83 | KDM4E (0.65) | KCNK3KCNK9KDM4ESLC2A1GAA | |
| SCHEMBL22364213 | 0.83 | KCNK3 (0.76) | KCNK3KCNK9KDM4ESLC2A1GAA | |
| SCHEMBL7228643 | 0.80 | KDM4E (0.64) | KCNK3KCNK9KDM4ESLC2A1GAA | |
| SCHEMBL18952321 | 0.79 | KCNK3 (0.93) | KCNK3KCNK9 | |
| SCHEMBL13234 | 0.79 | GABRA2 (0.63) | KCNK3KCNK9KDM4E | |
| SCHEMBL18963165 | 0.78 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL18963135 | 0.78 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963162 | 0.78 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18952242 | 0.78 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963158 | 0.77 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514969-B2 | Alzheimer's diseas, Parkinson disease, Huntington disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | HTT, APP, BACE1 | KCNK3 1661/4885KCNK9 2295/4885KDM4E 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.